IRD Earnings & Financial Statements
Opus Genetics, Inc.
$4.22
+$0.12(+2.80%)
45
Overall
40
Value
45
Tech
50
Quality
Market Cap
$341.10M
Volume
317.39K
52W Range
$1.70 - $7.07
Target Price
$12.17
IRD earnings and financial statements: Opus Genetics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
IRD Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $14.20M | $10.99M | $19.05M | $39.85M | $589.0K |
| Operating income | -$38.60M | -$62.07M | -$10.56M | $18.23M | -$22.70M |
| EBITDA | -$49.41M | -$57.52M | -$9.97M | $18.22M | -$56.69M |
| Net income | -$49.59M | -$57.53M | -$9.99M | $17.89M | -$56.69M |
| EPS (diluted) | $-0.80 | $-2.15 | $-0.46 | $0.87 | $-3.82 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $50.24M | $36.86M | $53.95M | $48.99M | $26.08M |
| Total liabilities | $34.90M | $11.29M | $4.04M | $2.75M | $3.85M |
| Shareholders’ equity | $15.35M | $6.72M | $49.91M | $46.24M | $22.22M |
| Cash and equivalents | $45.10M | $30.32M | $50.50M | $42.63M | $24.53M |
| Long-term debt | $1.13M | - | - | - | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$35.25M | -$25.58M | -$1.11M | $14.31M | -$19.37M |
| Free cash flow | -$35.25M | -$25.58M | -$1.11M | $14.31M | -$19.37M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IRD | $4.22 | +2.8% | 317.39K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |